Transcatheter closure of perimembranous ventricular septal defects: Initial human experience with the Amplatzer® membranous VSD occluder 2

Catheterization and Cardiovascular Interventions

Volumn 82, Issue 3, 2013, Pages 474-479

  Velasco Sanchez, Daniel ^a   Tzikas, Apostolos ^b   Ibrahim, Reda ^b   Mirõ, Joaquim ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Amplatzer; occluder; perimembranous ventricular septal defect

Indexed keywords

ANTIBIOTIC AGENT; HEPARIN;

ADULT; ANGIOGRAPHY; ARTICLE; CASE REPORT; CHILD; CLINICAL FEATURE; DIAPHORESIS; DYSPNEA; EQUIPMENT DESIGN; FEMALE; FOLLOW UP; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM DEFECT; HEPATOMEGALY; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; PERIMEMBRANOUS VENTRICULAR SEPTAL DEFECT; PHYSICAL EXAMINATION; PRESCHOOL CHILD; SEPTAL OCCLUDER; SYSTOLIC HEART MURMUR; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME;

AMPLATZER; OCCLUDER; PERIMEMBRANOUS VENTRICULAR SEPTAL DEFECT;

ADULT; CARDIAC CATHETERIZATION; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FEMALE; HEART SEPTAL DEFECTS, VENTRICULAR; HUMANS; MALE; PROSTHESIS DESIGN; SEPTAL OCCLUDER DEVICE; TREATMENT OUTCOME;

EID: 84883211796     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24361     Document Type: Article

References (12)

1. Hoffman JI, Kaplan S,. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39: 1890-1900.
2. Gatzoulis MA, Webb GD, Daubeneyet P,. Diagnosis and Management of Adult Congenital Heart Disease, 2nd ed. Philadelphia: Elsevier; 2011. p 171.
3. Jacobs JP, Burke RP, Quintessenza JA, Mavroudis C,. Congenital Heart Surgery Nomenclature and Database Project: Ventricular septal defect. Ann Thorac Surg 2000; 69: S25-S35.
4. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the management of adults with congenital heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008; 118: e714-e833.
5. Baumgartner H, Bonhoeffer P, De Groot NM, et al. Task force on the management of grown-up congenital heart disease of the European Society of Cardiology (ESC). ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010; 31: 2915-2957.
6. Hijazi ZM, Hakim F, Haweleh AA, et al. Catheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD occluder: Initial clinical experience. Catheter Cardiovasc Interv 2002; 56: 508-515.
7. Masura J, Gao W, Gavora P, et al. Percutaneous closure of perimembranous ventricular septal defects with the eccentric Amplatzer device: Multicenter follow-up study. Pediatr Cardiol 2005; 26: 216-219.
8. Fu YC, Bass J, Amin Z, et al. Transcatheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD occluder: Results of the U.S. phase I trial. J Am Coll Cardiol 2006; 47: 319-325.
9. Holzer R, de Giovanni J, Walsh KP, et al. Transcatheter closure of perimembranous ventricular septal defects using the amplatzer membranous VSD occluder: Immediate and midterm results of an international registry. Catheter Cardiovasc Interv 2006; 68: 620-628.
10. Butera G, Carminati M, Chessa M, et al. Transcatheter closure of perimembranous ventricular septal defects: Early and long-term results. J Am Coll Cardiol 2007; 50: 1189-1195.
11. Predescu D, Chaturvedi RR, Friedberg MK, Benson LN, Ozawa A, Lee KJ,. Complete heart block associated with device closure of perimembranous ventricular septal defects. J Thorac Cardiovasc Surg 2008; 136: 1223-1228.
12. Bass JL, Gruenstein D,. Transcatheter closure of the perimembranous ventricular septal defect-Preclinical trial of a new amplatzer device. Catheter Cardiovasc Interv 2012; 79: 1153-1160.